Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Genetics Receives NYSE Non-Compliance Notice

NEW YORK (GenomeWeb News) – Interleukin Genetics said Friday that it has received notification from the New York  Stock Exchange Alternext that the firm is not in compliance with certain listing criteria.

Specifically, the firm’s stockholders' equity is less than $6 million and it has reported losses from continuing operations and net losses in its five most recent fiscal years.

The company has a right to submit a plan of compliance to the exchange by Jan. 23, advising the exchange of what steps it has taken or intends to take to regain compliance with listing standards by June 23, 2010. If the exchange accepts the plan, Interleukin would continue to list on the Alternext. However, If the firm fails to submit such a plan, the plan is not accepted, it does not make progress toward compliance consistent with the plan, or is not in compliance at the end of the plan period, then it may be subject to delisting proceedings.

Interleukin said that it has begun developing its plan to regain compliance and intends to make a timely submission to the exchange in which it will outline the actions and timeframe by which it intends to regain listing compliance.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.